drugset / Trial / NCT03423810

Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

NCT03423810

Phase 0 Completed 14 enrolled University of Kansas Medical Center
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.

Timeline

Start
2018-04-23
Primary completion
2020-01-30
Completion
2020-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydralazine Small molecule 50 mg Oral